Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

INTRODUCTION: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). METHODS: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (Amst)
Main Authors: Carlson, Christopher, Siemers, Eric, Hake, Ann, Case, Michael, Hayduk, Roza, Suhy, Joyce, Oh, Joonmi, Barakos, Jerome
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2016
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879647/
https://ncbi.nlm.nih.gov/pubmed/27239538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2016.02.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados